新光药业
(300519)
| 流通市值：14.74亿 | | | 总市值：20.67亿 |
| 流通股本：1.14亿 | | | 总股本：1.60亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 216,211,460.22 | 146,210,038.02 | 100,545,259.3 | 270,399,837.67 |
| 营业收入 | 216,211,460.22 | 146,210,038.02 | 100,545,259.3 | 270,399,837.67 |
| 二、营业总成本 | 177,847,718.97 | 121,638,716.42 | 76,153,559.49 | 203,773,231.62 |
| 营业成本 | 140,364,926.08 | 96,499,935.86 | 62,812,898.25 | 158,795,336.02 |
| 税金及附加 | 3,511,891.38 | 2,328,183.57 | 1,645,256.87 | 4,361,787.75 |
| 销售费用 | 16,940,449.67 | 11,467,532.3 | 5,961,742.51 | 26,454,267.67 |
| 管理费用 | 11,724,886.84 | 8,242,833.93 | 3,676,940.35 | 17,918,334.79 |
| 研发费用 | 9,618,279.84 | 6,955,621.03 | 3,945,710.79 | 15,134,245.96 |
| 财务费用 | -4,312,714.84 | -3,855,390.27 | -1,888,989.28 | -18,890,740.57 |
| 其中:利息收入 | 4,323,126.6 | 3,863,048.33 | 1,892,311.55 | - |
| 加:投资收益 | 3,616,936.63 | 2,489,949.25 | 1,095,815.46 | 4,072,720.41 |
| 资产处置收益 | -67,847.01 | -67,847.01 | -67,847.01 | -290,571.95 |
| 资产减值损失(新) | -213,487.85 | -197,905.55 | -377,437.08 | -503,339.21 |
| 信用减值损失(新) | -390,429.15 | -1,983.45 | 121,762.8 | 708,142.15 |
| 其他收益 | 2,024,123.24 | 1,589,094.46 | 844,197.51 | 3,519,474.93 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 43,333,037.11 | 28,382,629.3 | 26,008,191.49 | 74,133,032.38 |
| 加:营业外收入 | 300,974 | 300,974 | 188,474 | 31,243.46 |
| 减:营业外支出 | 1,006,700 | 6,700 | 6,700 | 1,004,171.5 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 42,627,311.11 | 28,676,903.3 | 26,189,965.49 | 73,160,104.34 |
| 减:所得税费用 | 4,844,951.36 | 3,169,234.01 | 3,359,624.13 | 8,803,623.69 |
| 六、净利润 | 37,782,359.75 | 25,507,669.29 | 22,830,341.36 | 64,356,480.65 |
| 持续经营净利润 | 37,782,359.75 | 25,507,669.29 | 22,830,341.36 | 64,356,480.65 |
| 归属于母公司股东的净利润 | 37,782,359.75 | 25,507,669.29 | 22,830,341.36 | 64,356,480.65 |
| (一)基本每股收益 | 0.24 | 0.16 | 0.14 | 0.4 |
| (二)稀释每股收益 | 0.24 | 0.16 | 0.14 | 0.4 |
| 八、其他综合收益 | 16,614.39 | -231,393.57 | -407,242.18 | 869,736.31 |
| 归属于母公司股东的其他综合收益 | 16,614.39 | -231,393.57 | -407,242.18 | 869,736.31 |
| 九、综合收益总额 | 37,798,974.14 | 25,276,275.72 | 22,423,099.18 | 65,226,216.96 |
| 归属于母公司股东的综合收益总额 | 37,798,974.14 | 25,276,275.72 | 22,423,099.18 | 65,226,216.96 |
| 公告日期 | 2024-10-24 | 2024-08-27 | 2024-04-26 | 2024-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |